Literature DB >> 34517052

Novel quaternary structures of the human prion protein globular domain.

Leandro Oliveira Bortot1, Victor Lopes Rangel1, Francesca A Pavlovici2, Kamel El Omari3, Armin Wagner3, Jose Brandao-Neto3, Romain Talon3, Frank von Delft4, Andrew G Reidenbach2, Sonia M Vallabh2, Eric Vallabh Minikel2, Stuart Schreiber5, Maria Cristina Nonato6.   

Abstract

Prion disease is caused by the misfolding of the cellular prion protein, PrPC, into a self-templating conformer, PrPSc. Nuclear magnetic resonance (NMR) and X-ray crystallography revealed the 3D structure of the globular domain of PrPC and the possibility of its dimerization via an interchain disulfide bridge that forms due to domain swap or by non-covalent association of two monomers. On the contrary, PrPSc is composed by a complex and heterogeneous ensemble of poorly defined conformations and quaternary arrangements that are related to different patterns of neurotoxicity. Targeting PrPC with molecules that stabilize the native conformation of its globular domain emerged as a promising approach to develop anti-prion therapies. One of the advantages of this approach is employing structure-based drug discovery methods to PrPC. Thus, it is essential to expand our structural knowledge about PrPC as much as possible to aid such drug discovery efforts. In this work, we report a crystallographic structure of the globular domain of human PrPC that shows a novel dimeric form and a novel oligomeric arrangement. We use molecular dynamics simulations to explore its structural dynamics and stability and discuss potential implications of these new quaternary structures to the conversion process.
Copyright © 2021 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Amyloid; Anomalous scattering; Prion; X-ray crystallography

Mesh:

Substances:

Year:  2021        PMID: 34517052      PMCID: PMC8627497          DOI: 10.1016/j.biochi.2021.09.005

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  61 in total

1.  Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process.

Authors:  Sangho Lee; David Eisenberg
Journal:  Nat Struct Biol       Date:  2003-08-03

Review 2.  A general model of prion strains and their pathogenicity.

Authors:  John Collinge; Anthony R Clarke
Journal:  Science       Date:  2007-11-09       Impact factor: 47.728

3.  Inference of macromolecular assemblies from crystalline state.

Authors:  Evgeny Krissinel; Kim Henrick
Journal:  J Mol Biol       Date:  2007-05-13       Impact factor: 5.469

Review 4.  Hereditary Human Prion Diseases: an Update.

Authors:  Matthias Schmitz; Kathrin Dittmar; Franc Llorens; Ellen Gelpi; Isidre Ferrer; Walter J Schulz-Schaeffer; Inga Zerr
Journal:  Mol Neurobiol       Date:  2016-06-20       Impact factor: 5.590

Review 5.  Towards a treatment for genetic prion disease: trials and biomarkers.

Authors:  Sonia M Vallabh; Eric Vallabh Minikel; Stuart L Schreiber; Eric S Lander
Journal:  Lancet Neurol       Date:  2020-03-18       Impact factor: 44.182

Review 6.  The genetics of prion diseases.

Authors:  James A Mastrianni
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

Review 7.  Pharmacological Agents Targeting the Cellular Prion Protein.

Authors:  Maria Letizia Barreca; Nunzio Iraci; Silvia Biggi; Violetta Cecchetti; Emiliano Biasini
Journal:  Pathogens       Date:  2018-03-07

Review 8.  The biological function of the cellular prion protein: an update.

Authors:  Marie-Angela Wulf; Assunta Senatore; Adriano Aguzzi
Journal:  BMC Biol       Date:  2017-05-02       Impact factor: 7.431

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Evaluating drug targets through human loss-of-function genetic variation.

Authors:  Eric Vallabh Minikel; Konrad J Karczewski; Hilary C Martin; Beryl B Cummings; Nicola Whiffin; Daniel Rhodes; Jessica Alföldi; Richard C Trembath; David A van Heel; Mark J Daly; Stuart L Schreiber; Daniel G MacArthur
Journal:  Nature       Date:  2020-05-27       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.